Cart
sales@molnova.com
TP-16
CAS No. 2332972-26-4
TP-16( —— )
Catalog No. M35651 CAS No. 2332972-26-4
TP-16 is a novel potent and selective EP4 antagonist that blocks the function of IMCs and enhances cytotoxic T cell-mediated tumor elimination in vivo.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 377 | In Stock |
|
| 5MG | 610 | In Stock |
|
| 10MG | 820 | In Stock |
|
| 25MG | 1207 | In Stock |
|
| 100MG | Get Quote | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameTP-16
-
NoteResearch use only, not for human use.
-
Brief DescriptionTP-16 is a novel potent and selective EP4 antagonist that blocks the function of IMCs and enhances cytotoxic T cell-mediated tumor elimination in vivo.
-
DescriptionTP-16 is a novel and selective EP4 antagonist with an IC50 of 2.1 nM.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayGPCR/G Protein
-
TargetProstaglandin Receptor
-
RecptorProstaglandin Receptor
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2332972-26-4
-
Formula Weight439.5
-
Molecular FormulaC24H22FNO4S
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESC(N[C@@H](C)C1=CC=C(C(O)=O)C=C1)(=O)C=2C3=C(SC2CC4=CC=C(F)C=C4)COCC3
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Lu W, et al. Reprogramming immunosuppressive myeloid cells facilitates immunotherapy for colorectal cancer. EMBO Mol Med. 2021 Jan 11;13(1):e12798. ?
molnova catalog
related products
-
MF-766
MF-766 is a highly potent, selective and orally active EP4 antagonist with a Ki of 0.23 nM. It behaves as a full antagonist with an IC50 of 1.4 nM (shifted to 1.8 nM in the presence of 10% HS) in the functional assay. It can be used for cancer and inflammation diseases research.
-
4-Oxofenretinide
4-oxo-fenretinide, a recently identified fenretinide metabolite, induces marked G2-M cell cycle arrest and apoptosis.
-
Evatanepag
Evatanepag is an EP2 receptor selective prostaglandin E2 (PGE2) agonist that induces local bone formation with EC50 of 0.3 nM.
